Abstract
The blood‐testis barrier (BTB) prevents the entry of many therapeutics into the lumen of the seminiferous tubules (STs) shielding semen from chemical exposure. The BTB is formed by tight junctions between Sertoli cells. One drug class of HIV therapeutics, nucleoside analogs (NSAs), can penetrate the BTB and be detected in the semen. The purpose of this study is to determine the mechanisms by which NSAs are transported across the BTB. Transport studies in isolated rodent STs using H3uridine (Kt 89.72uM) as a model nucleoside substrate indicate that Sertoli cells take up nucleosides almost exclusively via equilibrative nucleoside transporter 1 (ENT1). The IC50 for NBMPR, an ENT inhibitor, is 12.9 nM. These data correspond with immunohistochemical staining of rat testes showing ENT1 on the basolateral membrane, whereas ENT2 is on the apical membrane of Sertoli cells. This localization suggests that ENT1 acts as an uptake transporter and ENT2 may facilitate the efflux of NSAs into the lumen of STs. Uptake of didanosine, a commonly used NSA, in HEK293 cells can be blocked by ENT1 inhibition. Trans‐epithelial transport of uridine by primary rat Sertoli cells can also be blocked by NBMPR. These data indicate a novel ENT1 and 2‐dominant mechanism for the transepithelial transport of nucleoside analogs across the BTB. AI083927.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
